The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Beyond acquisitions, we continue to expect steady future dividends, supported by a payout ratio of close to 50% relative to adjusted earnings per share. Patents, economies of scale, and a powerful ...

美国 FDA 肿瘤药咨询专家委员会于 9 月 26 日以 10 票赞成、2 票反对、1 票弃权的投票结果，决定默沙东的 Keytruda（帕博利珠单抗）和百时美施贵宝（BMS）的 Opdivo（纳武利尤单抗）作为一线治疗药对于生物标志物 PD-L1 检测呈阴性的胃癌患者无效。这一投票结果符合专家会成员、FDA 审评人员和申办人的共识，即当 PD-L1 ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...

在其他近期新闻中，Summit Therapeutics在有希望的临床试验数据发布后受到金融公司的重点关注。Stifel将Summit Therapeutics的目标价上调至40.00美元，而H.C. Wainwright将其目标价调整至45.00美元，两家公司均维持买入评级。这些调整是基于最近的临床试验数据和在重要医学会议上的演讲，突出了Summit的药物ivonescimab的潜力。

Silicon Valley accelerator Y Combinator held the second Demo Day for its Summer 2024 cohort on Thursday, and just like we saw ...

An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.

The days of broad stomach cancer labels for PD-1 inhibitors appear to be numbered.  | The days of broad stomach cancer labels ...